Featured Research

from universities, journals, and other organizations

Pioneering The Basics For New Kind Of Cancer Vaccine

Date:
August 3, 2004
Source:
Mayo Clinic
Summary:
Mayo Clinic and British researchers have developed a new approach to cancer vaccines that purposely kills healthy skin cells to target the immune system against tumors.

ROCHESTER, Minn. -- Mayo Clinic and British researchers have developed a new approach to cancer vaccines that purposely kills healthy skin cells to target the immune system against tumors. The new approach has eradicated skin cancer tumors in mice. The approach and results challenge conventional thinking on the creation of cancer vaccines. Their report on the "heat shock" vaccine therapy appears in the August issue of Nature Biotechnology, (http://www.nature.com/nbt/). Results are promising because multiple rounds of treatment eradicated skin cancer in all the mice in the study. If this work can be extended to humans, it could have enormous benefits. Skin cancer is currently the most common form of cancer in the United States, with an estimated one million new cases diagnosed annually.

Related Articles


Significance of the Mayo Clinic Research

Normally, the destruction of healthy cells is undesirable. For example, in toxic conventional chemotherapies for cancer, the goal is to kill cancer cells and spare healthy cells. This new approach is significant for two reasons:

1) It turns the death of healthy cells into a therapeutic advantage by inflicting a stress known as "inflammatory cell death" on skin cells to which researchers attached a protein involved in heat shock. Researchers were able to trigger a healing immune response aimed at the skin cancer tumors. The response was so strong it eradicated the tumors.

2) Researchers avoided triggering autoimmune attacks, which are a common disabling side effect of most cancer vaccine attempts. In autoimmune attacks the body attacks and injures itself -- instead of the cancer. This new approach appears to breach a major obstacle to advancing cancer vaccine research from the laboratory into human trials.

"We're very encouraged by these results because our main interest is in generating cancer vaccines that will stimulate the immune system to recognize tumors and eradicate them. We hope our novel approach will be a more specific, and therefore gentler therapy for patients," says Mayo immunologist and lead researcher Richard Vile, Ph.D.

Background

To test the idea that killing normal cells might trigger a specific immune system response, the team chose normal skins cells called melanocytes that are involved in the highly lethal cancer malignant melanoma. The researchers created a molecular scout to home in on and kill some of the melanocytes in mice. To the molecular scout they attached an unusual protein, called heat shock protein 70, or hsp70. It normally is not present in healthy cells, but when cells die under certain conditions, they release hsp70. "It's a danger-signal system that the body is in trouble," says Dr. Vile. "We hoped to trigger an anti-tumor response."

The unanticipated result was a two-step reaction with promising traits that may one day help skin cancer patients. In the first step, the heat shock protein recruited T cells -- the main warriors of the immune system -- that attacked melanocytes. The T cells killed all tumors in the mice.

Researchers also questioned whether a raging T-cell attack might prompt autoimmune disease. The immune system apparently anticipated that. In response to the vaccine, it sent out regulatory T cells to calm down the first group of fighting T cells.

Says Dr. Vile: "The nice twist is that originally we thought we would generate a very potent autoimmune disease before we killed the tumor. But we found just the opposite. What happens is that you get a burst of T cells that kill the melanoma, and then they are suppressed by regulatory T cells in the mouse before they cause autoimmune disease."

For humans, this is good news. "This is very hopeful because we think in the clinic there are good chances we can control anti-tumor effects before we get to the autoimmune problems," says Dr. Vile.

The Next Step

The researchers will pursue two basic paths. One will extend the current work on a heat shock vaccine to other tissue and tumor types to determine its effectiveness against breast, lung or prostate cancers. The other is to test this immunotherapy in clinical trials with humans.

In addition to Dr. Vile, co-investigators are: Gregory Daniels, M.D., Ph.D.; Luis Sanchez Perez; Rosa Maria Diaz, Ph.D.; Timothy Kottke; Jill Thompson; Maoyi Lai; Michael Gough; Mahzuz Karim and Andrew Bushell, Ph.D., Oxford University; Heung Chong; Alan Melcher, Ph.D., Cancer Research UK, Leeds; and Kevin Harrington, Ph.D., Institute of Cancer Research, London. Their work was supported by grants from the Mayo Foundation and the National Institutes of Health.


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Cite This Page:

Mayo Clinic. "Pioneering The Basics For New Kind Of Cancer Vaccine." ScienceDaily. ScienceDaily, 3 August 2004. <www.sciencedaily.com/releases/2004/08/040801230247.htm>.
Mayo Clinic. (2004, August 3). Pioneering The Basics For New Kind Of Cancer Vaccine. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2004/08/040801230247.htm
Mayo Clinic. "Pioneering The Basics For New Kind Of Cancer Vaccine." ScienceDaily. www.sciencedaily.com/releases/2004/08/040801230247.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins